A US vaccine firm has opened the first mRNA manufacturing plant in the UK, against a backdrop of increasing anti-jab rhetoric back home.
The new facility outside Oxford is part of a £1bn investment in the UK by Moderna, which specialises in mRNA.
The novel vaccine technology delivered some of the most effective and fastest-to-develop jabs during the COVID pandemic.
Several pharma companies, including Germany’s leading mRNA pioneer BioNTech, are now racing to develop new therapies.
Moderna says the plant will produce up to 100 million doses of its existing vaccine products each year. It has also been designed to scale-up production to 250 million doses a year in the event of a new disease outbreak.
“God-forbid, if there is another pandemic, we can switch the facility any day,” said Moderna CEO Stephane Bancel.
The UK investment deal was agreed by the previous government, but the plant’s opening is welcome relief for the current one.
In recent weeks, four major pharmaceutical companies have halted planned investments in the UK following disputes over drug pricing and profitability in the UK.
‘A great statement’
It also promises to restore domestic vaccine manufacturing capability in the UK, the lack of which was exposed when dangerous supply interruptions threatened the early COVID response.
“It’s a really fast way of getting new vaccines discovered,” said Lord Patrick Vallance, former chief scientist and now science minister.
“It’s also a great statement of confidence in the UK that [Moderna has] chosen to base themselves here.”
Health Secretary Wes Streeting attended the opening
The Trump effect
The mRNA molecule is the same used by our cells to order the production of new proteins, and allows vaccines to be produced using just the genetic code of a virus or other biological target.
Moderna’s investment decision pre-dated Donald Trump’s return to the White House, but the Moderna CEO said its operation in the UK – a country that “still believes in vaccination” – may pay dividends if anti-vaccine rhetoric translates into a lack of demand for its products in the US.
“If there is less appetite by governments around the world, including in the US, to use vaccines, we might invest less in vaccines,” said Mr Bancel.
“We have to invest where there’s a demand for our products.”
Read more: All health claims made by Trump – and what experts say
Please use Chrome browser for a more accessible video player
Is US politics fuelling a deadly measles outbreak?
The UK presents other attractions for the company which has suffered substantial losses as demand for its COVID vaccine has fallen.
It’s betting that leading UK universities and a large patient population will make for successful clinical trials.
The company has ongoing NHS trials of new jabs against seasonal flu, a combination COVID and flu vaccine, cancer vaccines and mRNA therapies for two inherited childhood diseases.
Moderna says it is now the largest private commercial sponsor of clinical trials in the UK.
